Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Procter & Gamble
PGConsumer StaplesGenerated Jul 5, 2026, 08:08 PM UTC
PG (Procter & Gamble) analytical snapshot. Revenue grew +2.3% YoY to $82.01B. Net margin at 17.87% (contracting ▼). Return on equity 31.27%, ROA 11.97%, ROIC 38.70%. Market cap $352.57B at $151.41 per share. Trailing P/E 25.66, P/S 4.30, P/B 6.44. EV/Operating income ≈ 20.20 (EV $366.40B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score 9 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Market cap
$352.57B
2.33B shares
Price
$151.41
NYQ
P/E (ttm)
25.66
Revenue (FY)
$82.01B
YoY +2.3%
Net margin
17.87%
▼ 0.49pp
Free cash flow
$13.79B
16.81% margin
Risk level
Moderate
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 25Improving
80% conf
Revenue grew +2.3% YoY to $82.01B. Net margin at 17.87% (contracting ▼). Return on equity 31.27%, ROA 11.97%, ROIC 38.70%.
- Revenue grew +2.3% YoY to $82.01B.
- Net margin at 17.87% (contracting ▼).
- Return on equity 31.27%, ROA 11.97%, ROIC 38.70%.
- Gross margin 0.00%, operating margin 22.11%.
- Free cash flow margin 16.81% ($13.79B).
- Net income down ▼ +0.6% YoY.
- Debt/equity 0.42, current ratio 0.73, net debt $13.82B.
- Asset turnover 0.64 — capital efficiency.
Revenue (FY)
$82.01B
YoY +2.3%
Net margin
17.87%
▼ 0.49pp
ROE
31.27%
ROA 11.97%
ROIC
38.70%
EPS (diluted)
$5.90
FY2025
Free cash flow
$13.79B
16.81% margin
Debt / equity
0.42
Cash $9.30B
Current ratio
0.73
Equity $54.73B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | $10.11B | 16.95 |
| 2017 | — | — | — | — | — | $10.87B | 10.05 |
| 2018 | — | — | — | — | — | $12.12B | 16.67 |
| 2019 | $65.06B | — | 0.00 | 21.16 | 23.56 | $9.37B | 26.43 |
| 2020 | $66.83B | +2.7% | 0.00 | 19.99 | 14.59 | $11.15B | 17.48 |
| 2021 | $67.68B | +1.3% | 0.00 | 8.11 | 5.76 | $11.89B | 7.37 |
| 2022 | $70.95B | +4.8% | 0.00 | 22.14 | 18.36 | $14.33B | 27.38 |
| 2023 | $76.12B | +7.3% | 0.00 | 23.63 | 18.79 | $15.58B | 30.52 |
| 2024 | $80.19B | +5.3% | 0.00 | 22.21 | 18.38 | $13.57B | 31.60 |
| 2025 | $82.01B | +2.3% | 0.00 | 22.11 | 17.87 | $13.79B | 31.27 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $19.78B | -68.9% | — | 62.49% |
| Sep 30, 2025 | $22.39B | +3.0% | +13.2% | 21.22% |
| Dec 31, 2025 | $44.59B | +2.2% | +99.2% | 20.34% |
| Dec 31, 2025 | $22.21B | -49.1% | -50.2% | 40.84% |
| Mar 31, 2026 | $65.83B | +3.8% | +196.4% | 19.75% |
| Mar 31, 2026 | $21.23B | -66.5% | -67.7% | 61.23% |
Revenue (annual, SEC 10-K)
2016: 0
2017: 0
2018: 0
2019: 65,058
2020: 66,832
2021: 67,684
2022: 70,950
2023: 76,118
2024: 80,187
2025: 82,006
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 10,110
2017: 10,872
2018: 12,121
2019: 9,369
2020: 11,150
2021: 11,895
2022: 14,330
2023: 15,584
2024: 13,567
2025: 13,786
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 25Improving
80% conf
Latest quarterly report (10-Q) filed Apr 24, 2026. 13 recent 8-K material-event filings in the index. Recent insider Form 4s: 0 buy vs 0 sell transactions.
- Latest quarterly report (10-Q) filed Apr 24, 2026.
- 13 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Procter & Gamble; broad institutional reporting.
- Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 6 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 14 recent 13G passive institutional ownership notices.
Latest 10-K
—
Latest 10-Q
Apr 24, 2026
8-K (recent)
13
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
6
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 15, 2003 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Feb 12, 2004 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Aug 9, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Feb 11, 2003 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Nov 2, 2001 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Apr 24, 2026 | 8-K | 8-K |
| Apr 24, 2026 | 8-K | FY2526 Q3 JFM 8-K |
| Apr 14, 2026 | 8-K | 8-K |
| Jan 22, 2026 | 8-K | 8-K |
| Jan 22, 2026 | 8-K | FY2526 Q2 OND 8-K |
| Jan 13, 2026 | 8-K | 8-K |
| Dec 15, 2025 | 8-K | 8-K |
| Nov 4, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -34Deteriorating
70% conf
2 risk signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 2 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Material weakness in internal controls in latest filing: The term "material weakness" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 20 filing(s).
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 2 filing(s).
- Goodwill is 32% of total assets: Goodwill of $41.36B represents a large share of the balance sheet. If acquired businesses underperform, a non-cash impairment charge could materially impact earnings. Monitor segment performance and acquisition integration metrics.
- Endogenous analysis: 2 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 2 new risk-language term(s) detected in filing text: Material weakness in internal controls, Restatement of financial statements.
Revenue
$82.01B
+2.3% YoY
Operating income
$18.13B
+1.8% YoY
Net income
$14.65B
-0.6% YoY
Operating cash flow
$16.85B
+0.7% YoY
Capex
$3.06B
-3.0% YoY
Total assets
$122.37B
+4.4% YoY
Total liabilities
$71.81B
-2.6% YoY
Long-term debt
$26.43B
-0.0% YoY
Filing quality score
62/100
1 new disclosures
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $80.19B | $82.01B | $1.82B | +2.3% |
| Operating income | $17.81B | $18.13B | $321.0M | +1.8% |
| Net income | $14.74B | $14.65B | $-89.0M | -0.6% |
| Operating cash flow | $16.72B | $16.85B | $125.0M | +0.7% |
| Capex | $3.16B | $3.06B | $-94.0M | -3.0% |
| Total assets | $117.21B | $122.37B | $5.16B | +4.4% |
| Total liabilities | $73.76B | $71.81B | $-1.95B | -2.6% |
| Long-term debt | $26.43B | $26.43B | $-1.0M | -0.0% |
| Cash & equivalents | $6.84B | $8.10B | $1.26B | +18.5% |
| Stockholders equity | $46.65B | $46.85B | $200.0M | +0.4% |
| Inventory | $7.07B | $7.02B | $-57.0M | -0.8% |
| Accounts receivable | $5.47B | $6.12B | $647.0M | +11.8% |
| R&D expense | $2.00B | $2.00B | $0 | 0.0% |
| SG&A expense | $20.22B | $21.11B | $895.0M | +4.4% |
| Interest expense | $465.0M | $502.0M | $37.0M | +8.0% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Added | RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated |
| Removed | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, AdvertisingExpense, CommercialPaper, CommonStockParOrStatedValuePerShare, CommonStockSharesAuthorized, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DeferredFederalIncomeTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Material weakness in internal controls | high | 20 | 0 | NEW |
| Restatement of financial statements | high | 2 | 0 | NEW |
| Impairment charge | medium | 52 | 8 | Ongoing |
| Restructuring | medium | 122 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 30 | 2 | Ongoing |
| Related party transactions | low | 30 | 0 | NEW |
Filing signal breakdown
Red flags: 2
Positive: 0
Watch: 1
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $352.57B at $151.41 per share.
- ProPrice & TechnicalsPrice $151.41 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Moderate.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite 9
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Procter & Gamble is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewRevenue grew **+2.3%** YoY to $82.01B..
Risk
Moderate
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow PG stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Procter & Gamble PG● you | 9 | Neutral |
| CVS Health Corp. CVS | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Danaher Corp. DHR | — | Neutral |
| Intuitive Surgical Inc. ISRG | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |
| Regeneron Pharmaceuticals REGN | — | Neutral |
| Gilead Sciences GILD | — | Neutral |
| Zoetis Inc. ZTS | — | Neutral |
| Colgate-Palmolive CL | — | Neutral |
| Kimberly-Clark Corp. KMB | — | Neutral |
| Hershey Co. HSY | — | Neutral |
| Sysco Corp. SYY | — | Neutral |
| Kroger Co. KR | — | Neutral |
| Moderna Inc. MRNA | — | Neutral |
| Biogen Inc. BIIB | — | Neutral |
| DexCom Inc. DXCM | — | Neutral |
| Illumina Inc. ILMN | — | Neutral |
| HCA Healthcare HCA | — | Neutral |
| Cigna Group CI | — | Neutral |